For the quarter ended December 2025, Abbott (ABT) reported revenue of $11.46 billion, up 4.4% over the same period last year. EPS came in at $1.50, compared to $1.34 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $11.78 billion, representing a surprise of -2.76%. The company delivered an EPS surprise of +0.2%, with the consensus EPS estimate being $1.50.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net sales- Nutrition- U.S.: $806 million versus the five-analyst average estimate of $897.76 million. The reported number represents a year-over-year change of -13.2%.
- Net sales- Diagnostics- International: $1.49 billion versus the five-analyst average estimate of $1.5 billion. The reported number represents a year-over-year change of +1.7%.
- Net sales- Diagnostics- U.S.: $967 million versus $1.04 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -8.3% change.
- Net sales- Nutrition- International: $1.13 billion versus the five-analyst average estimate of $1.3 billion. The reported number represents a year-over-year change of -5.6%.
- Net sales- Diagnostics: $2.46 billion compared to the $2.54 billion average estimate based on seven analysts. The reported number represents a change of -2.5% year over year.
- Net sales- Nutrition: $1.94 billion compared to the $2.2 billion average estimate based on seven analysts. The reported number represents a change of -8.9% year over year.
- Net sales- Medical Devices: $5.68 billion versus the six-analyst average estimate of $5.68 billion. The reported number represents a year-over-year change of +12.3%.
- Net sales- Established Pharmaceuticals: $1.38 billion versus the six-analyst average estimate of $1.38 billion. The reported number represents a year-over-year change of +9%.
- Net sales- Medical Devices- Diabetes Care: $2.13 billion versus $2.15 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +14.5% change.
- Net sales- Medical Devices- Vascular- Total: $783 million versus $768.92 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8% change.
- Net sales- Medical Devices- Neuromodulation- Total: $274 million versus the five-analyst average estimate of $270.37 million. The reported number represents a year-over-year change of +6.6%.
- Net sales- Medical Devices- Structural Heart- Total: $675 million versus the five-analyst average estimate of $668.07 million. The reported number represents a year-over-year change of +10.8%.
View all Key Company Metrics for Abbott here>>>
Shares of Abbott have returned -3.3% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
